Michael D Rasmussen

US Patent:

6437106, Aug 20, 2002

Filed:

Mar 3, 2000

Appl. No.:

09/518281

Inventors:

Eric J. Stoner - Kenosha WI
Matthew J. Peterson - Gurnee IL
Yi-Yin Ku - Buffalo Grove IL
Russell D. Cink - Grayslake IL
Arthur J. Cooper - Lake Villa IL
Mahendra N. Deshpande - Gurnee IL
Tim Grieme - Chicago IL
Anthony R. Haight - Wadsworth IL
David R. Hill - Gurnee IL
Margaret Chi-Ping Hsu - Vernon Hills IL
Steven A. King - Gurnee IL
Marvin Robert Leanna - Grayslake IL
Elaine C. Lee - Mundelein IL
Maureen A. McLaughlin - Evanston IL
Howard E. Morton - Gurnee IL
James J. Napier - Antioch IL
Daniel J. Plata - Wadsworth IL
Prasad S. Raje - Lindenhurst IL
Michael Rasmussen - Kenosha WI
David Riley - Kenosha WI
Steven J. Wittenberger - Mundelein IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C07H 100

US Classification:

536 74, 536 72, 536 185

Abstract:

In one aspect, the invention relates to a process for preparing 6-O-substituted erythromycin derivatives comprising reacting 2â-substituted and optionally 4â-substituted 9-oxime erythromycin derivatives with an alkylating agent in the presence of a palladium catalyst and phosphine. In another aspect, the invention relates to processes for preparing 6-O-substituted erythromycin ketolides using the palladium-catalyzed alkylation reaction.

US Patent:

7812032, Oct 12, 2010

Filed:

Jul 23, 2007

Appl. No.:

11/781804

Inventors:

Shekhar Viswanath - Vernon Hills IL, US
Larry Bartelt - Highland Park IL, US
Robert Leanna - Grayslake IL, US
Michael Rasmussen - Racine WI, US
Madhup Dhaon - Mundelein IL, US
Rodger Henry - Wildwood IL, US
Thomas Borchardt - Kenosha WI, US
Shuang Chen - Gurnee IL, US
Geoff Zhang - Libertyville IL, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C07D 498/18
A61K 31/395

US Classification:

514291, 540456

Abstract:

A rapamycin analog composition includes a crystalline form of a rapamycin analog. The crystal can be a hydrate, dehydrate, solvate, or desolvate. The rapamycin analog can have a structure of Formula 1, which is optionally a prodrug, salt, derivative, or combination thereof:.

US Patent:

7820812, Oct 26, 2010

Filed:

Jul 23, 2007

Appl. No.:

11/781807

Inventors:

Shekhar Viswanath - Vernon Hills IL, US
Larry Bartelt - Highland Park IL, US
Robert Leanna - Grayslake IL, US
Michael Rasmussen - Racine WI, US
Madhup Dhaon - Mundelein IL, US
Rodger Henry - Wildwood IL, US
Thomas Borchardt - Kenosha WI, US
Shuang Chen - Gurnee IL, US
Geoff Zhang - Libertyville IL, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C07D 498/18

US Classification:

540456

Abstract:

A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.

US Patent:

8034926, Oct 11, 2011

Filed:

Sep 20, 2010

Appl. No.:

12/886398

Inventors:

Shekhar Viswanath - Vernon Hills IL, US
Larry Bartelt - Highland Park IL, US
Robert Leanna - Grayslake IL, US
Michael Rasmussen - Racine WI, US
Madhup Dhaon - Mundelein IL, US
Rodger Henry - Wildwood IL, US
Thomas Borchardt - Kenosha WI, US
Shuang Chen - Gurnee IL, US
Geoff Zhang - Libertyville IL, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C07D 498/18

US Classification:

540456

Abstract:

A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.

US Patent:

20060063825, Mar 23, 2006

Filed:

Sep 19, 2005

Appl. No.:

11/230043

Inventors:

Walter Dziki - Libertyville IL, US
Ziqi Lu - Vernon Hills IL, US
Michael Rasmussen - Racine WI, US
Jaqueline Wardrop - Evanston IL, US
Geoff Zhane - Libertyville IL, US
Cathie Linton - Waukegan IL, US

International Classification:

A61K 31/4025
C07D 405/02

US Classification:

514422000, 548526000

Abstract:

Atrasentan Hydrochloride Crystalline Form 2, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.

US Patent:

20110009325, Jan 13, 2011

Filed:

Sep 20, 2010

Appl. No.:

12/886410

Inventors:

SHEKHAR VISWANATH - Vernon Hills IL, US
Larry Bartelt - Highland Park IL, US
Robert Leanna - Grayslake IL, US
Michael Rasmussen - Racine WI, US
Madhup Dhaon - Mundelein IL, US
Rodger Henry - Wildwood IL, US
Thomas Borchardt - Kenosha WI, US
Shuang Chen - Gurnee IL, US
Geoff Zhang - Libertyville IL, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

A61K 31/436
A61K 31/437
A61K 31/7048
A61K 31/704
A61K 31/662
A61K 38/12
A61K 38/06
A61K 38/16
A61K 31/573
A61K 31/565
A61P 35/00
A61P 29/00
A61P 37/02
A61P 9/00

US Classification:

514 139, 514291, 514283, 514 27, 514 34, 514115, 514 138, 514179, 514182, 514180

Abstract:

Provided is a rapamycin analog composition including a crystalline form of a rapamycin analog. The crystal can be a hydrate. dehydrate, solvate, or desolvate. The rampamycin analog can have a structure of Formula 1, which is optionally a prodrug, salt, derivative, or combination thereof:

US Patent:

20120028908, Feb 2, 2012

Filed:

Oct 1, 2011

Appl. No.:

13/251207

Inventors:

Shekhar VISWANATH - Vernon Hills IL, US
Larry Bartelt - Highland Park IL, US
Robert Leanna - Grayslake IL, US
Michael Rasmussen - Racine WI, US
Madhup Dhaon - Mundelein IL, US
Rodger Henry - Wildwood IL, US
Thomas Borchardt - Kenosha WI, US
Shuang Chen - Gurnee IL, US
Geoff Zhang - Libertyville IL, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

A61K 38/16
A61K 31/437
A61K 31/7048
A61P 35/00
A61K 31/565
A61K 31/56
C07D 498/12
A61K 31/5365
A61K 31/573

US Classification:

514 192, 514291, 514285, 514 27, 514171, 540456

Abstract:

A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.